Tirzepatide may cut CV events in high-risk type 2 diabetes

Clinical takeaway: For patients with type 2 diabetes and established cardiovascular disease, tirzepatide may offer cardiovascular benefit beyond glucose and weight control.

Tirzepatide has established benefits for glycemic control and weight loss, but its incremental effect on major cardiovascular events has been less clear. A large real-world study now suggests that starting tirzepatide may reduce cardiovascular risk when added to contemporary diabetes care.

Researchers analyzed US insurance claims from 52,971 adults aged 40 or older with type 2 diabetes, overweight or obesity, and established atherosclerotic cardiovascular disease. Patients starting tirzepatide were compared with those starting sitagliptin, which has been shown to have a neutral effect on cardiovascular outcomes and was used as a placebo-like comparator.

At one year, the estimated risk of a major adverse cardiovascular event—heart attack, stroke, or death from any cause—was 2.9% with tirzepatide versus 4.4% with sitagliptin, a 32% relative reduction. That translates to about one fewer event for every 70 patients starting tirzepatide.

The difference was driven primarily by lower risks of heart attack and all-cause mortality. Tirzepatide was associated with a 33% lower risk of heart attack, while ischemic stroke risk did not meaningfully differ between groups. Hospitalizations for infections and infection-related deaths were also lower with tirzepatide, raising the possibility of benefits beyond atherosclerotic pathways.

The study was observational, and the authors cautioned that residual differences between patients receiving the two drugs could partly explain the mortality findings. Follow-up was also relatively short. Still, the results help put the potential cardiovascular benefit of initiating tirzepatide into absolute terms that clinicians can use when discussing treatment options with high-risk patients.

“This study shows how trial-anchored evidence from clinical practice can estimate the expected cardiovascular benefit of initiating tirzepatide beyond standard background treatment and inform shared decision making,” the study authors concluded.

Source: Krüger N, et al. (2026 Aug 5) BMJ. Tirzepatide and the risk of atherosclerotic cardiovascular events: population based cohort study